Full text is available at the source.
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
How GIP Might Improve the Treatment Effects of GLP-1
AI simplified
Abstract
Dual GIP/GLP-1 receptor agonist therapy may produce profound weight loss and improvements in glycemic control and lipid levels in type 2 diabetes mellitus.
- Glucagon-like peptide-1 (GLP-1) receptor agonists are known to enhance glucose regulation and reduce body weight.
- Dosing of GLP-1 receptor agonists can lead to gastrointestinal side effects that may limit their effectiveness.
- Engineering GLP-1 activity into glucose-dependent insulinotropic polypeptide (GIP) could expand therapeutic options.
- The interplay between GIP and GLP-1 may improve lipid and glucose metabolism, particularly when GIP's lipogenic actions are considered.
- Recent findings suggest that combining GIP and GLP-1 receptor agonists may optimize treatment outcomes in managing type 2 diabetes.
AI simplified